Sanofi

Latest stories

15m
FOX Business
The Next Stock Warren Buffett May Sellat this point. But if my arm were twisted, I could see the Oracle of Omaha and
The Next Stock Warren Buffett May Sell
FOX Business / Posted 15 minutes ago
at this point. But if my arm were twisted, I could see the Oracle of Omaha and his team parting ways with French drugmaker Sanofi . As of the latest 13-F filing with the Securities and Exchange Commission, Buffett's Berkshire Hathawayowned... Read more
15m
FOX Business
The Next Stock Warren Buffett May Sellat this point. But if my arm were twisted, I could see the Oracle of Omaha and
The Next Stock Warren Buffett May Sell
FOX Business / Posted 15 minutes ago
at this point. But if my arm were twisted, I could see the Oracle of Omaha and his team parting ways with French drugmaker Sanofi . As of the latest 13-F filing with the Securities and Exchange Commission, Buffett's Berkshire Hathawayowned... Read more
1d
The Manila Times
French drug giant Sanofi vows hostile bid for US preyApril 30, 2016 11:10 am PARIS: French pharmaceutical giant Sanofi vowed to ope
French drug giant Sanofi vows hostile bid for US prey
The Manila Times / Posted yesterday
April 30, 2016 11:10 am PARIS: French pharmaceutical giant Sanofi vowed to open a hostile takeover battle Friday after its $9.3 billion (8.2 million-euro) offer for US cancer drug maker Medivation... Read more
31 related stories
1d
Investopedia
DODFX: Dodge & Cox International Stock Fund Performance Case Studyemerging market, at 4.2% of assets. Samsung Electronics Co. Ltd. (OTC: SSNLF) r
DODFX: Dodge & Cox International Stock Fund Performance Case Study
Investopedia / Posted yesterday
emerging market, at 4.2% of assets. Samsung Electronics Co. Ltd. (OTC: SSNLF) represents 3.8% of the portfolio, followed by Sanofi (NYSE: SNY) with 3.7%. Due to accelerating capital inflows, the fund announced that it was closing its doors to new... Read more
8 related stories
1d
Channel NewsAsia
US stocks drop as retailers hit by weak consumer datacompany, Medivation, rose 2.9 per cent after turning down an unsolicited US$9.3
US stocks drop as retailers hit by weak consumer data
Channel NewsAsia / Posted yesterday
company, Medivation, rose 2.9 per cent after turning down an unsolicited US$9.3 billion bid from French pharma giant Sanofi. US shares of Sanofi, which vowed to take its hostile offer to shareholders, fell 4.1 per cent. US oil giant... Read more
1d
San Francisco Chronicle
Biotech firm Medivation rejects $9.3 billion Sanofi offerMedivation snubbed French pharmaceutical giant Sanofi’s bid to buy the San Fran
Biotech firm Medivation rejects $9.3 billion Sanofi offer
San Francisco Chronicle / Posted yesterday
Medivation snubbed French pharmaceutical giant Sanofi’s bid to buy the San Francisco cancer drugmaker, calling the $9.3 billion takeover offer “substantially inadequate.” On Friday, Medivation officials said the company’s board of directors... Read more
31 related stories
2d
News-Medical-Net
New version of obesity drug could help people reduce weight without experiencing anxiety, depressionin a small number of the people who took it. Because of this, the drug was neve
New version of obesity drug could help people reduce weight without experiencing anxiety, depression
News-Medical-Net / Posted 2 days ago
in a small number of the people who took it. Because of this, the drug was never approved in the US and manufacturer Sanofi-Aventis pulled from the European market voluntarily. In the new study, the researchers altered the drug so it no... Read more
2d
Swissinfo
AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bid(Bloomberg) -- AstraZeneca Plc and Pfizer Inc. are among firms considering a co
AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bid
Swissinfo / Posted 2 days ago
(Bloomberg) -- AstraZeneca Plc and Pfizer Inc. are among firms considering a counteroffer for Medivation Inc., challenging Sanofi’s $9.3 billion bid for the company, people familiar with the matter said. Novartis AG is also exploring a bid, said... Read more
31 related stories
2d
Bangkok Post - Thailand's English news
French drug giant Sanofi vows hostile bid for US preyPARIS - French pharmaceutical giant Sanofi vowed to open a hostile takeover bat
French drug giant Sanofi vows hostile bid for US prey
Bangkok Post - Thailand's English news / Posted 2 days ago
PARIS - French pharmaceutical giant Sanofi vowed to open a hostile takeover battle Friday after its $9.3 billion (8.2 million-euro) offer for US cancer drug maker Medivation was dismissed for being too cheap. Sanofi, the 11th largest pharmaceutical... Read more
31 related stories
2d
The China Post
US biotech firm Medivation rejects Sanofi takeover bid NEW YORK -- U.S. biotech company Medivation rejected an unsolicited US$9.3 bi
US biotech firm Medivation rejects Sanofi takeover bid
The China Post / Posted 2 days ago
NEW YORK -- U.S. biotech company Medivation rejected an unsolicited US$9.3 billion bid from French pharmaceuticals giant Sanofi Friday, saying the offer "substantially undervalues" the company.... Read more
31 related stories
2d
The Record Searchlight
Medivation rejects Sanofi bid, Sanofi to go to shareholdersNEW YORK (AP) - Drug maker Sanofi says it is still committed to its $9.3 billio
Medivation rejects Sanofi bid, Sanofi to go to shareholders
The Record Searchlight / Posted 2 days ago
NEW YORK (AP) - Drug maker Sanofi says it is still committed to its $9.3 billion acquisition offer for Medivation, even though the pharmaceutical firm has rejected its bid. Sanofi has offered $52.50 per Medivation share. Medivation said Friday that... Read more
31 related stories
2d
Channel NewsAsia
Medivation board rejects Sanofi's US$9.3 billion takeover offerREUTERS: Medivation Inc said on Friday its board rejected an unsolicited US$9.3
Medivation board rejects Sanofi's US$9.3 billion takeover offer
Channel NewsAsia / Posted 2 days ago
REUTERS: Medivation Inc said on Friday its board rejected an unsolicited US$9.3 billion takeover proposal from Sanofi SA , saying the offer undervalued the company and its pipeline of oncology drugs. The French drugmaker went public with its... Read more
31 related stories
2d
Channel NewsAsia
US biotech firm Medivation rejects Sanofi takeover bidNEW YORK: US biotech company Medivation rejected an unsolicited US$9.3 billion
US biotech firm Medivation rejects Sanofi takeover bid
Channel NewsAsia / Posted 2 days ago
NEW YORK: US biotech company Medivation rejected an unsolicited US$9.3 billion bid from French pharmaceuticals giant Sanofi Friday (Apr 29), saying the offer "substantially undervalues" the company. Medivation, which makes the lucrative prostate... Read more
31 related stories
2d
Reuters
Medivation board rejects Sanofi's $9.3 billion takeover offerThe Sanofi logo is seen at the company's Sanofi Pasteur headquarters in Lyon, F
Medivation board rejects Sanofi's $9.3 billion takeover offer
Reuters / Posted 2 days ago
The Sanofi logo is seen at the company's Sanofi Pasteur headquarters in Lyon, France, October 26, 2015. French drugs firm Sanofi will present its Q3 results on October 29. Medivation Inc (MDVN.O) said on Friday its board rejected an unsolicited $9.3... Read more
31 related stories
2d
MedCity News
Sanofi makes $9.3B offer for Medivation, Alere says it rejected Abbott's request to scrap M&A dealSanofi is making a play for oncology drug developer Medivation to the tune of $
Sanofi makes $9.3B offer for Medivation, Alere says it rejected Abbott's request to scrap M&A deal
MedCity News / Posted 2 days ago
Sanofi is making a play for oncology drug developer Medivation to the tune of $9.3 billion in what could be a big showdown between it and other pharma companies seeking to strengthen their oncology product pipelines. The company has one cancer drug... Read more
2d
TheStreet.com
Sanofi First Quarter Shows Why it Wants but Doesn't Need MedivationSanofi's net profit for the quarter was €1.72 billion ($1.96 billion) down 0.2%
Sanofi First Quarter Shows Why it Wants but Doesn't Need Medivation
TheStreet.com / Posted 2 days ago
Sanofi's net profit for the quarter was €1.72 billion ($1.96 billion) down 0.2% on a year earlier, though up 3.5% once exchange-rate movements are stripped out. The results beat many analyst estimates but failed to ignite Sanofi shares, which dropped... Read more
31 related stories
2d
Channel NewsAsia
AstraZeneca cuts costs and doubles down on cancer drugswas now full. He declined to comment specifically on whether AstraZeneca would
AstraZeneca cuts costs and doubles down on cancer drugs
Channel NewsAsia / Posted 2 days ago
was now full. He declined to comment specifically on whether AstraZeneca would consider getting into a bidding war with Sanofi over U.S. cancer treatment specialist Medivation. To free resources for investment, AstraZeneca has been selling off... Read more
3 related stories
2d
The Economic Times
Sanofi India posts 25 per cent rise in Q1 net profiteffect from April 2016. "Consequently the company has reduced prices of such p
Sanofi India posts 25 per cent rise in Q1 net profit
The Economic Times / Posted 2 days ago
effect from April 2016. "Consequently the company has reduced prices of such products. This will have an adverse impact on the sales and profitability of the company," it added. Sanofi India stock was trading at Rs 4,380, up 1.36 per cent, on... Read more
2d
Channel NewsAsia
Sanofi confident it can win Medivation shareholder supportPARIS: Sanofi , which reported higher quarterly profit on Friday boosted by its
Sanofi confident it can win Medivation shareholder support
Channel NewsAsia / Posted 2 days ago
PARIS: Sanofi , which reported higher quarterly profit on Friday boosted by its Genzyme division, is confident Medivation shareholders will back its proposed takeover of the U.S. cancer drug company. The French drugmaker went public on Thursday with... Read more
31 related stories
2d
Reuters
Sanofi confident it can win Medivation shareholder supportFrench multinational pharmaceutical company SANOFI logo is seen at the headquar
Sanofi confident it can win Medivation shareholder support
Reuters / Posted 2 days ago
French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. PARIS Sanofi (SASY.PA), which reported higher quarterly profit on Friday boosted by its Genzyme division, is confident Medivation... Read more
31 related stories
2d
The Economic Times
Sanofi confident can win Medivation shareholder support for bidwill ultimately share our strong belief that our offer (...) would provide sign
Sanofi confident can win Medivation shareholder support for bid
The Economic Times / Posted 2 days ago
will ultimately share our strong belief that our offer (...) would provide significant and immediate cash value," Sanofi Chief Executive Olivier Brandicourt said on a conference call. Chief Financial Officer Jerome Contamine refused to... Read more
2d
Your Hometown Lima Stations
Sanofi profits stable, strong sales in emerging marketsPARIS (AP) - Sanofi says drugs sales in emerging markets helped keep its profit
Sanofi profits stable, strong sales in emerging markets
Your Hometown Lima Stations / Posted 2 days ago
PARIS (AP) - Sanofi says drugs sales in emerging markets helped keep its profits stable in the first quarter despite losses caused by Venezuela's collapsing currency. With early efforts for a Zika vaccine and several other drugs in the pipeline,... Read more
2 related stories
2d
Market Watch
Sanofi CEO seeks talks with Medivation over offerPARIS--Sanofi SA Chief Executive Olivier Brandicourt said Friday that he hoped
Sanofi CEO seeks talks with Medivation over offer
Market Watch / Posted 2 days ago
PARIS--Sanofi SA Chief Executive Olivier Brandicourt said Friday that he hoped Medivation Inc. management would come to the negotiating table in coming weeks after he went public with an unsolicited offer worth $9.3 billion for the U.S. biotech... Read more
31 related stories
2d
Island Packet
Sanofi profits stable, strong sales in emerging marketsSanofi says drugs sales in emerging markets helped keep its profits stable in t
Sanofi profits stable, strong sales in emerging markets
Island Packet / Posted 2 days ago
Sanofi says drugs sales in emerging markets helped keep its profits stable in the first quarter despite losses caused by Venezuela's collapsing currency. With early efforts for a Zika vaccine and several other drugs in the pipeline, Sanofi is trying... Read more
2 related stories
2d
Daily Herald
Sanofi profits stable, strong sales in emerging marketsPARIS -- Sanofi says drugs sales in emerging markets helped keep its profits st
Sanofi profits stable, strong sales in emerging markets
Daily Herald / Posted 2 days ago
PARIS -- Sanofi says drugs sales in emerging markets helped keep its profits stable in the first quarter despite losses caused by Venezuela's collapsing currency. With early efforts for a Zika vaccine and several other drugs in the pipeline, Sanofi... Read more
2 related stories
2d
CNBC
Sanofi confident can win Medivation shareholder support for bidwill ultimately share our strong belief that our offer (...) would provide sign
Sanofi confident can win Medivation shareholder support for bid
CNBC / Posted 2 days ago
will ultimately share our strong belief that our offer (...) would provide significant and immediate cash value," Sanofi Chief Executive Olivier Brandicourt said on a conference call. Chief Financial Officer Jerome Contamine refused to... Read more
2d
Market Watch
Sanofi profit lifted by biotech, emerging marketsPARIS--French drugmaker Sanofi SA on Friday reported a rise in first-quarter ne
Sanofi profit lifted by biotech, emerging markets
Market Watch / Posted 2 days ago
PARIS--French drugmaker Sanofi SA on Friday reported a rise in first-quarter net profit, lifted by its biotech unit and emerging markets. The Paris-based drugmaker said net profit increased by 6% to EUR1.09 billion ($1.24 billion) for the three... Read more
2d
Daily Herald
Despite wave of deals, stocks slip as economic growth slowsand it rocketed $17.09, or 27.6 percent, to $79.04 while Abbott fell $2.99, or
Despite wave of deals, stocks slip as economic growth slows
Daily Herald / Posted 2 days ago
and it rocketed $17.09, or 27.6 percent, to $79.04 while Abbott fell $2.99, or 6.8 percent, to $40.84. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
2d
TribLIVE
Sell-off dings stock marketgoing to come out guns blazing” to stimulate their economies. A handful of sto
Sell-off dings stock market
TribLIVE / Posted 2 days ago
going to come out guns blazing” to stimulate their economies. A handful of stocks moved on deal news. French drugmaker Sanofi went public with an offer to buy cancer drugmaker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
2d
The Middletown Press
US stocks skid as Apple pulls tech companies lowerby low-interest rates on loans and the fact that companies have been slashing t
US stocks skid as Apple pulls tech companies lower
The Middletown Press / Posted 2 days ago
by low-interest rates on loans and the fact that companies have been slashing their expenses for years. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
2d
The Columbian
U.S. stocks skid as Apple pulls tech companies loweradded, by low interest rates on loans and the fact that companies have been sla
U.S. stocks skid as Apple pulls tech companies lower
The Columbian / Posted 2 days ago
added, by low interest rates on loans and the fact that companies have been slashing expenses for years. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
2d
San Francisco Chronicle
Bay Area biotech firms Medivation, Stemcentrx get takeover bidstwo Bay Area biotechnology firms in efforts to expand their portfolios of drugs
Bay Area biotech firms Medivation, Stemcentrx get takeover bids
San Francisco Chronicle / Posted 2 days ago
two Bay Area biotechnology firms in efforts to expand their portfolios of drugs to treat cancer. Giant French drugmaker Sanofi made an unsolicited offer Thursday to buy San Francisco’s Medivation for $9.3 billion. Also on Thursday,... Read more
31 related stories
2d
TheBull
US stocks falter on Icahn remarks as BoJ hold fire$25 billion in cash and shares. Abbott lost 7.8 percent. A second big healthca
US stocks falter on Icahn remarks as BoJ hold fire
TheBull / Posted 2 days ago
$25 billion in cash and shares. Abbott lost 7.8 percent. A second big healthcare deal also looked possible as drugmaker Sanofi went public with a an all-cash $9.3 billion offer for Medivation, saying the US company repeatedly refused to engage... Read more
2d
Connecticut Post
WALL STREET PAYDAY: Banks could make up to $340 million from Takeover ThursdayEvercore, Guggenheim Securities, and Centerview Partners. Morgan Stanley also
WALL STREET PAYDAY: Banks could make up to $340 million from Takeover Thursday
Connecticut Post / Posted 2 days ago
Evercore, Guggenheim Securities, and Centerview Partners. Morgan Stanley also had a big day, advising both Stemcentrx and Sanofi. Altogether, Wall Street banks will bring in up to $342 million in fees for advising and arranging financing on... Read more
2 related stories
2d
San Francisco Chronicle
WALL STREET PAYDAY: Banks could make up to $340 million from Takeover ThursdayEvercore, Guggenheim Securities, and Centerview Partners. Morgan Stanley also
WALL STREET PAYDAY: Banks could make up to $340 million from Takeover Thursday
San Francisco Chronicle / Posted 2 days ago
Evercore, Guggenheim Securities, and Centerview Partners. Morgan Stanley also had a big day, advising both Stemcentrx and Sanofi. Altogether, Wall Street banks will bring in up to $342 million in fees for advising and arranging financing on... Read more
2 related stories
2d
Stamford Advocate
WALL STREET PAYDAY: Banks could make up to $340 million from Takeover ThursdayEvercore, Guggenheim Securities, and Centerview Partners. Morgan Stanley also
WALL STREET PAYDAY: Banks could make up to $340 million from Takeover Thursday
Stamford Advocate / Posted 2 days ago
Evercore, Guggenheim Securities, and Centerview Partners. Morgan Stanley also had a big day, advising both Stemcentrx and Sanofi. Altogether, Wall Street banks will bring in up to $342 million in fees for advising and arranging financing on... Read more
2 related stories
2d
Your Hometown Lima Stations
US stocks skid as Apple pulls tech companies lowerby low interest rates on loans and the fact that companies have been slashing t
US stocks skid as Apple pulls tech companies lower
Your Hometown Lima Stations / Posted 2 days ago
by low interest rates on loans and the fact that companies have been slashing their expenses for years. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
2d
Boston Globe
US stocks skid as Apple pulls tech companies lowermoved some stocks. Abbott Laboratories will buy St. Jude Medical; St. Jude surg
US stocks skid as Apple pulls tech companies lower
Boston Globe / Posted 2 days ago
moved some stocks. Abbott Laboratories will buy St. Jude Medical; St. Jude surged 25.6 percent as Abbott fell 7.8 percent. Sanofi offered $9.3 billion for drug maker Medivation (up 7.9 percent). AbbVie (up 0.9 percent) will buy privately held... Read more
225 related stories
2d
Channel NewsAsia
US stocks tumble as Apple hit by Icahn exit of sharesUS$3.8 billion. Comcast fell 0.2 per cent. Pharmaceutical company Medivation c
US stocks tumble as Apple hit by Icahn exit of shares
Channel NewsAsia / Posted 2 days ago
US$3.8 billion. Comcast fell 0.2 per cent. Pharmaceutical company Medivation climbed 7.9 per cent after French drug giant Sanofi made an unsolicited all-cash US$9.3 billion takeover offer for the company. Medivation, known for the lucrative... Read more
2d
FOX Business
Sanofi's Bid for Medivation Is Too LowImage source: Flickr user StockMonkeys.com. After waiting for weeks for a repl
Sanofi's Bid for Medivation Is Too Low
FOX Business / Posted 2 days ago
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation. Sanofi's purchase price is substantially... Read more
31 related stories
2d
FOX Business
Sanofi's Bid for Medivation Is Too LowFlickr user StockMonkeys.com. Continue Reading Below After waiting for weeks
Sanofi's Bid for Medivation Is Too Low
FOX Business / Posted 2 days ago
Flickr user StockMonkeys.com. Continue Reading Below After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation. Sanofi's purchase price is... Read more
31 related stories
2d
The Lexington Dispatch
Big deals and gains for tech stocks lead US indexes higherand it rocketed $17.25, or 27.8 percent, to $79.20 while Abbott fell $2.28, or
Big deals and gains for tech stocks lead US indexes higher
The Lexington Dispatch / Posted 2 days ago
and it rocketed $17.25, or 27.8 percent, to $79.20 while Abbott fell $2.28, or 5.2 percent, to $41.55. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
2d
Your Hometown Lima Stations
US stocks slide as economic growth disappoints, tech weakensand it rocketed 16.64, or 26.9 percent, to $78.59 while Abbott fell $2.71, or 6
US stocks slide as economic growth disappoints, tech weakens
Your Hometown Lima Stations / Posted 2 days ago
and it rocketed 16.64, or 26.9 percent, to $78.59 while Abbott fell $2.71, or 6.2 percent, to $41.12. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
2d
Channel NewsAsia
AbbVie forges deeper into cancer, as clock ticks for Humiralung cancer. A similar new drug from Merck & Co also has a list price of US$150
AbbVie forges deeper into cancer, as clock ticks for Humira
Channel NewsAsia / Posted 2 days ago
lung cancer. A similar new drug from Merck & Co also has a list price of US$150,000. Also on Thursday, French drugmaker Sanofi announced its US$9.3 billion offer to buy Medivation, which makes prostate cancer treatment Xtandi. Stemcentrx's... Read more
32 related stories
3d
The Register NorthJersey.com
U.S. stocks slip following report on slower economyand it rocketed 16.64, or 26.9 percent, to $78.59 while Abbott fell $2.71, or 6
U.S. stocks slip following report on slower economy
The Register NorthJersey.com / Posted 3 days ago
and it rocketed 16.64, or 26.9 percent, to $78.59 while Abbott fell $2.71, or 6.2 percent, to $41.12. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
3d
Your Hometown Lima Stations
US stocks slip as economic growth disappointsand it rocketed $16.94, or 27.3 percent, to $78.89 while Abbott fell $2.56, or
US stocks slip as economic growth disappoints
Your Hometown Lima Stations / Posted 3 days ago
and it rocketed $16.94, or 27.3 percent, to $78.89 while Abbott fell $2.56, or 5.8 percent, to $41.27. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
3d
Reuters
AbbVie forges deeper into cancer, as clock ticks for Humirafor, unlike some other therapeutic categories where they are putting pressure o
AbbVie forges deeper into cancer, as clock ticks for Humira
Reuters / Posted 3 days ago
for, unlike some other therapeutic categories where they are putting pressure on price. Also on Thursday, French drugmaker Sanofi (SASY.PA) went public with its $9.3 billion offer to buy Medivation (MDVN.O), which makes prostate cancer treatment... Read more
32 related stories
3d
TheStreet.com
investors should flock to pharmaannounced a $9.8 billion deal to buy Stemcentrx, a venture-backed combatant in
investors should flock to pharma
TheStreet.com / Posted 3 days ago
announced a $9.8 billion deal to buy Stemcentrx, a venture-backed combatant in small cell lung cancer, while France's Sanofi SA (SA) went public in a campaign to buy Medivation Inc. (MDVN). Sanofi's chief executive complained that a $9.3... Read more
3d
The Morning Call
Sanofi makes $9.3 billion bid for American firm MedivationPARIS (AP) — Drug maker Sanofi made a $9.3 billion bid for San Francisco pharma
Sanofi makes $9.3 billion bid for American firm Medivation
The Morning Call / Posted 3 days ago
PARIS (AP) — Drug maker Sanofi made a $9.3 billion bid for San Francisco pharmaceutical firm Medivation on Thursday, part of the firm's effort to expand its portfolio of cancer treatments. Medivation Inc. has so far resisted overtures from... Read more
31 related stories
3d
Your Hometown Lima Stations
Deals, gains for tech stocks lead US indexes mostly higherand it rocketed $16.96, or 27.4 percent, to $78.91 while Abbott fell $2.47, or
Deals, gains for tech stocks lead US indexes mostly higher
Your Hometown Lima Stations / Posted 3 days ago
and it rocketed $16.96, or 27.4 percent, to $78.91 while Abbott fell $2.47, or 5.6 percent, to $41.13. French drugmaker Sanofi went public with an offer to buy cancer drug maker Medivation for $9.3 billion, or $52.50 per share. Medivation, the... Read more
21 related stories
More

People in this news